Evidence Intelligence™
- EvidenceScore™
- 75
- Strong
- ImpactScore™
- 65
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Dulaglutide may improve weight loss in obese patients with diabetes
Última actualización 4 de julio de 2026
Key finding
The patient achieved a weight loss of 40 kg (−21%) over 6 months.
This study evaluated the effects of Dulaglutide on weight loss in a morbidly obese patient with type 2 diabetes, resulting in significant weight reduction and improved glycemic control.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Non-randomized CT
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of Dulaglutide on weight loss in a morbidly obese patient with type 2 diabetes, resulting in significant weight reduction and improved glycemic control.
Clinical relevance
This study highlights the potential of Dulaglutide as a therapeutic option for weight management in patients with type 2 diabetes, addressing a critical aspect of diabetes care. Effective weight loss can lead to improved health outcomes and reduced complications associated with obesity and diabetes.
Keep in mind
Single participant limits generalizability. Non-randomized design may introduce bias. No long-term follow-up data available.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Sohail B, Sahil B, Grishma S, et al. Dulaglutide for Weight Loss in a Morbidly Obese Patient with Type 2 Diabetes. Clinical Case Reports. 2024;12(9):e9403. doi:10.1002/ccr3.9403
Efectos Principales
Weight loss of 40 kg (−21%) over 6 months.
BMI decreased by 10.3 kg/m² over 6 months.
Daily caloric intake reduced from 6924 to 2538.9 calories.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dulaglutide and BMI, Body weight, Caloric intake, and 2 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
- BMI
- Body weight
- Caloric intake
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
5
Evidence pairs
481
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Mass Index
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 58
- Emerging
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerGastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Dulaglutide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- 58
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 58
- Emerging
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- 40 kg weight loss observed in 6 months.
- 10.3 kg/m² reduction in BMI recorded.
- Daily caloric intake decreased by 4385.1 calories.
A quién se aplica
- Morbidly obese adults with type 2 diabetes.
- Patients seeking pharmacological weight loss options.
Tener en Cuenta
- Results are based on a single case study.
- Further research needed to confirm findings.
- Effectiveness in broader populations remains unclear.
Entre Líneas
- Single participant limits generalizability.
- Non-randomized design may introduce bias.
- No long-term follow-up data available.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Mass Index, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- 75
- Strong
- ImpactScore™
- 65
- Slightly Positive
- ConsistencyScore™
- 67
- generally_consistent
Estudios de apoyo: Basado en 3 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 76
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
3 studies
outcome_hubMeasures Body Mass Index as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
3 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dulaglutide and BMI
Intervention: DulaglutideOutcome: BMI
3 results
All studies on Dulaglutide and Body weight
Intervention: DulaglutideOutcome: Body weight
2 results
All studies on Dulaglutide
Intervention: Dulaglutide
3 results
All studies measuring BMI
Outcome: BMI
3 results
All studies measuring Body weight
Outcome: Body weight
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 75.4 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect gastrointestinal adverse events?
Strong Evidence
GLP-1 Receptor Agonists may worsen Gastrointestinal Adverse Events or be associated with harm.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Gastrointestinal disorders incidence
EvidenceScore™ Emerging | EvidenceScore™ 58.5 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve cgm time in range?
Moderate Evidence
GLP-1 Receptor Agonists may improve CGM Time in Range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Time to glycemic target
EvidenceScore™ Emerging | EvidenceScore™ 58.5 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
GLP-1 agonists reduce heart fat thickness in diabetes.Higher dulaglutide doses improve weight loss in type 2 diabetesDietary supplements may lower diabetes risk in prediabetesDigital intervention improves glycemic control in type 2 diabetes patientsLong BPL-RYGB improves HbA1c and weight loss in T2D patients
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.